Evidence map›Paper›PMID 38765766›Full record

ArticleInternational journal of chronic obstructive pulmonary disease2024

Disease Burden and Health-Related Quality of Life (HRQoL) of Chronic Obstructive Pulmonary Disease (COPD) in the US - Evidence from the Medical Expenditure Panel Survey (MEPS) from 2016-2019.

Melissa H Roberts, David M Mannino, Douglas W Mapel, Orsolya Lunacsek, Shahla Amin, Eileen Farrelly, Norbert Feigler, Michael F Pollack

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of chronic obstructive pulmonary disease, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Frailty in COPD: Clinical Impact, Diagnosis, Biomarkers, and Management Strategies.International journal of chronic obstructive pulmonary disease · 2025
    Pooled it
  3. Pooled it
  4. Article
  5. Exploring the Impact of Financial Toxicity in COPD: A Qualitative Study.Chronic obstructive pulmonary diseases (Miami, Fla.) · 2026
    Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Improving COPD Management at Transitions of Care.Federal practitioner : for the health care professionals of the VA, DoD, and PHS · 2024
    Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Melissa H RobertsCollege of Pharmacy, University of New Mexico, Albuquerque, NM, USA.ORCID 0000-0002-1314-4906
David M ManninoCollege of Medicine, University of Kentucky, Lexington, KY, USA.
Douglas W MapelNorthern Arizona Pulmonary Associates, Flagstaff, AZ, USA.ORCID 0000-0001-5208-4363
Orsolya LunacsekGlobal Consulting, Cencora, Conshohocken, PA, USA.
Shahla AminGlobal Consulting, Cencora, Conshohocken, PA, USA.
Eileen FarrellyGlobal Consulting, Cencora, Conshohocken, PA, USA.
Norbert FeiglerBioPharmaceuticals, US Medical, AstraZeneca, Wilmington, DE, USA.
Michael F PollackBioPharmaceuticals, US Medical, AstraZeneca, Wilmington, DE, USA.ORCID 0000-0001-7351-3059

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Chronic obstructive pulmonary disease (COPD) is a progressive disease associated with reduced life expectancy, increased morbidity, mortality, and cost. This study characterized the US COPD burden, including socioeconomic and health-related quality of life (HRQoL) outcomes. Study Design and Methods: In this retrospective, cross-sectional study using nationally representative estimates from Medical Expenditures Survey (MEPS) data (2016-2019), adults (≥18 years) living with and without COPD were identified. Adults living without COPD (control cohort) and with COPD were matched 5:1 on age, sex, geographic region, and entry year. Demographics, clinical characteristics, socioeconomic, and generic HRQoL measures were examined to include a race-stratified analysis of people living with COPD. Results: A total of 4,135 people living with COPD were identified; the matched dataset represented a weighted non-institutionalized population of 11.3 million with and 54.2 million people without COPD. Among people living with COPD, 66.3% had ≥1 COPD-related condition; 62.7% had ≥1 cardiovascular condition, compared to 33.5% and 50.5% without COPD. More people living with COPD were unemployed (56.2% vs 45.3%), unable to work due to illness/disability (30.1% vs 12.1%), had problems paying bills (16.1% vs 8.8%), reported poorer perceived health (fair/poor: 36.2% vs 14.4%), missed more working days due to illness/injury per year (median, 2.5 days vs 0.0 days), and had limitations in physical functioning (40.1% vs 19.4%) (all Conclusion: Adults living with COPD had higher clinical disease burden, lower socioeconomic status, and reduced HRQoL than those without, with greater disparities among Black people living with COPD compared to White and other races. Understanding the characteristics of patients helps address care disparities and access challenges.

Indexed as

Cost of IllnessHealth ExpendituresPulmonary Disease, Chronic ObstructiveQuality of LifeAdolescentAdultAgedComorbidityCross-Sectional StudiesFemaleHealth StatusHumansMaleMiddle AgedRetrospective StudiesSocioeconomic Factorsburden of illnessCOPDhealthcare costrace/ethnicity

Identifiers

PMID38765766
PMCPMC11100519

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.